Novartis Expands ADC Pipeline with $1.5B Myricx Bio Deal, Key Readouts Set H2
NVS•Novartis has agreed to acquire Myricx Bio for $1.5 billion, adding novel NMTi ADC payloads to its portfolio. Late-stage assets del-brax and pelacarsen target multibillion-dollar peak sales with pivotal data due in H2, though commercial impact remains years away.
1. Deal Details
Novartis will acquire Myricx Bio for $1.5 billion, unlocking novel NMTi payload technology intended to enhance its antibody–drug conjugate offerings.
2. Pipeline Implications
The acquisition extends Novartis’ ADC portfolio with Myricx’s NMTi mechanisms, positioning the company for longer-term growth while commercial launches remain years away.
3. Readout Timeline
Late-stage assets del-brax and pelacarsen are slated for pivotal data releases in the second half of the year, with both programs targeting multibillion-dollar peak sales.
